Cap analog modified with pace structure and use thereof

By replacing phosphonate with phosphonate acetic acid structure in the cap analog, the cap analog with PACE structure modified is solved, and the problem of insufficient mRNA immunogenicity in the prior art is achieved, and efficient mRNA translation and stability improvement is achieved .

WO2024227423A1PCT designated stage expired Publication Date: 2024-11-07JIANGSU SYNTHGENE BIOTECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/090513
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-04-29
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Existing cap analogs have insufficient immunogenicity in improving the biological activity and translation efficiency of mRNA, making it difficult to effectively improve the stability and translation efficiency of mRNA.

Method used

By replacing the phosphonate at the triphosphonate segment or phosphonate segment of the cap analog to the phosphonate acetic acid structure, the cap analog with PACE structure is constructed, and the alkyl-COOH or its salt group is increased, thereby improving the IVT yield and capping efficiency.

Benefits of technology

It significantly improves the translation efficiency and stability of mRNA, reduces immunogenicity, and enhances the biological activity of the target mRNA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024090513-FTAPPB-I100001
    Figure PCTCN2024090513-FTAPPB-I100001
  • Figure PCTCN2024090513-FTAPPB-I100002
    Figure PCTCN2024090513-FTAPPB-I100002
  • Figure PCTCN2024090513-FTAPPB-I100003
    Figure PCTCN2024090513-FTAPPB-I100003
Patent Text Reader

Abstract

Disclosed in the present invention is a cap analog modified with a PACE structure. The cap analog modified with the PACE structure has ribose bases or modified ribose bases at both ends, three ribose structures in the middle and a triphosphonate chain segment or phosphonate chain segment connected to the ribose structures, on the basis of an existing cap analog structure, and one or more PACE structures or PACE-derived structures are constructed on the triphosphate chain segment or phosphonate chain segment, that is, substituted or unsubstituted (alkoxy)alkyl-COOH or a salt thereof is present on the triphosphonic acid or phosphonic acid, so that the yield and capping efficiency of IVT are increased, and the translation efficiency of the target mRNA is improved.
Need to check novelty before this filing date? Find Prior Art

Description

A PACE structure-modified cap analogue and its application

[0001] This application claims priority to the Chinese patent application filed with the China Patent Office on May 4, 2023, with application number 2023104884119 and invention name “A PACE structure-modified cap analog and its application”, the entire contents of which are incorporated by reference into this application. Technical Field

[0002] The present invention relates to the technical field of chemistry and bioengineering, and in particular to a PACE structure-modified cap analogue and application thereof. Background Art

[0003] In eukaryotic cells, mRNA needs to have some key structures to perform its corresponding functions. These are mainly composed of five parts: the 5' cap structure (5'Cap), the 5' untranslated region (5'UTR), the open reading frame (ORF) encoding the antigen, the 3' untranslated region (3'UTR), and a poly (A) tail. Among them, the cap structure (Cap) plays a crucial role, which can improve the stability of mRNA structure, enhance translation efficiency, and reduce immunogenicity.

[0004] Autoimmune proteins such as RIGI and IFIT can recognize abnormally capped mRNA, reducing the activity and half-life of exogenous mRNA in cells, making it difficult for mRNA to function in vivo. Therefore, optimizing the mRNA cap structure (capping) is crucial for improving the biological activity of mRNA.

[0005] Summary of the Invention

[0006] To address the need for improved immunogenicity in existing cap analogs, the present invention provides a cap analog with a modified PACE structure, wherein one or more phosphonates are replaced with phosphonoacetic acid (salt) structures at the phosphorus positions of the triphosphonate segment or phosphonate segment between the three ribose structures of the cap analog. The cap analog with a modified PACE structure of the present invention, due to the presence of a substituted or unsubstituted (alkoxy)alkyl-COOH group or a salt thereof on the triphosphonate or phosphonate, not only improves IVT yield and capping efficiency, but also enhances the translation efficiency of the target mRNA.

[0007] The PACE structure-modified cap analogues of the present invention are based on the existing cap analogue structure, which has ribobases or modified ribobases at both ends, three ribose structures in the middle, and a triphosphonate segment or a phosphonate segment connecting the ribose structures. The present invention constructs one or more PACE structures or PACE-derived structures in the triphosphonate segment or the phosphonate segment, and the PACE structure or PACE-derived structure conforms to the following general structural formula:

[0008] X of the PACE structure is -CH2COOH or a salt thereof;

[0009] X in the PACE-derived structure is -COOH, substituted or unsubstituted alkyl-COOH or a salt thereof, substituted or unsubstituted O-alkyl-COOH or a salt thereof, substituted or unsubstituted alkyl-O-COOH or a salt thereof, substituted or unsubstituted alkyl-O-alkyl-COOH or a salt thereof; the carbon number of the alkyl group mentioned above is not greater than 7; the substituent group mentioned above refers to an alkyl group, alkenyl group, alkynyl group, cycloalkyl group or cycloalkenyl group having a carbon number not greater than 7.

[0010] The salt refers to a sodium salt, an ammonium salt or a salt formed with tris(hydroxymethyl)aminomethane. The salt formed by tris(hydroxymethyl)aminomethane and the cap analogue with modified PACE structure of the present invention is hereinafter referred to as tris salt.

[0011] Preferably, X is an alkyl-COOH group or a salt thereof, and the number of carbon atoms in the alkyl group is 1, 2, 3 or 4.

[0012] Preferably, X is O-alkyl-COOH, and the number of carbon atoms in the alkyl group is 1, 2, 3 or 4.

[0013] As a preference, the PACE structure-modified cap analogue conforms to the following general structural formula:

[0014] wherein R1, R2 and R3 are independently H, OH, F, alkyl, substituted or unsubstituted O-alkyl;

[0015] R4 is selected from OH or O-alkyl;

[0016] Any one, two or more of X1, X2, X3 and X4 are X according to claim 1, and the rest are each independently H, OH, NH2, alkyl, O-alkyl, N-alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or halogen;

[0017] B1 and B2 are each independently a natural, modified or unnatural nucleobase.

[0018] Preferably, R1, R2, and R3 are independently H, OH, F, C1-C4 alkyl, O-C1-C4 alkyl, or O-C1-C4 alkyl substituted with O-C1-C4 alkyl. Preferably, the C1-C4 alkyl group has 1, 2, 3, or 4 carbon atoms. Preferably, the O-C1-C4 alkyl group has 1, 2, 3, or 4 carbon atoms. More preferably, they are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, -OCH2OCH3, -OC2H4OCH3, or -OCH2OC2H5.

[0019] Preferably, R4 is selected from OH or O-C1-C4 alkyl, more preferably OH, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy.

[0020] As a preference, the PACE structure-modified cap analogue conforms to the following general structural formula:

[0021] wherein R1, R2 and R3 are independently H, OH, F, alkyl or O-alkyl;

[0022] Any one, two or more of X1, X2, X3 and X4 are X according to claim 1, and the rest are each independently H, OH, NH2, alkyl, O-alkyl, N-alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or halogen;

[0023] B1 and B2 are each independently a natural, modified or unnatural nucleobase.

[0024] Preferably, R1, R2, and R3 are independently H, OH, F, C1-C4 alkyl, O-C1-C4 alkyl, or O-C1-C4 alkyl substituted with O-C1-C4 alkyl. Preferably, the C1-C4 alkyl group has 1, 2, 3, or 4 carbon atoms. Preferably, the O-C1-C4 alkyl group has 1, 2, 3, or 4 carbon atoms. More preferably, they are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, -OCH2OCH3, -OC2H4OCH3, or -OCH2OC2H5.

[0025] Preferably, B1 and B2 are independently adenine (A), guanine (G), cytosine (C), uracil (U), thymine (T) or adenine substituted with a methyl group.

[0026] Preferably, B1 and B2 are each independently adenine (A), guanine (G) or adenine substituted with a methyl group.

[0027] In the above-mentioned adenine substituted with a methyl group, the substitution position of the methyl group is the hydrogen atom of the exocyclic amino group.

[0028] Furthermore, the PACE structure-modified cap analog is any one of the following structures:

[0029] The PACE structure-modified cap analog provided by the present invention may also be in the form of a salt, which may be a sodium salt, potassium salt, ammonium salt, organic amine salt, or other salt well known to those skilled in the art.

[0030] As a preference, the PACE structure-modified cap analog is a salt form of any one of the following structures, wherein the salt form is a sodium salt, an ammonium salt or a salt formed by tris(hydroxymethyl)aminomethane of the following structure:

[0031] The PACE structure-modified cap analogues of the present invention are used to cap RNA in an in vitro transcription reaction for in vitro transcription preparation of linear mRNA; the steps are as follows:

[0032] Step (1): preparing a DNA template;

[0033] Step (2): performing an in vitro transcription reaction, wherein the reaction system contains RNA polymerase, nucleoside triphosphonate and the PACE structure-modified cap analog.

[0034] The PACE-modified cap analogs of the present invention have a more stable conformation and are less susceptible to nuclease recognition and hydrolysis. Therefore, the PACE-modified cap analogs have the following advantages: (1) high IVT yield and capping efficiency; and (2) high translation efficiency of the target mRNA.

[0035] Explanation of terms

[0036] The terms "base", "natural base" and "nucleoside base" used herein may be used interchangeably, including but not limited to adenine (A), guanine (G), cytosine (C), uracil (U), or thymine (T).

[0037] "Modified bases" and "modified nucleoside bases" are used interchangeably and refer to substances in which one or more hydrogen atoms of a natural base are replaced, including but not limited to 7-methylguanine,

[0038] The "ribose structure" in the present invention includes but is not limited to and its isomers, derivatives, etc., structures in which any functional group is substituted, and isomers and derivatives thereof.

[0039] The "triphosphonate segment" in the present invention includes but is not limited to and isomers, derivatives, salts thereof, wherein one or more of X1, X2, and X3 is -COOH, -CH2COOH, substituted or unsubstituted alkyl-COOH, substituted or unsubstituted O-COOH, substituted or unsubstituted O-alkyl-COOH, substituted or unsubstituted alkyl-O-alkyl-COOH, etc.

[0040] The "phosphonate segments" of the present invention include but are not limited to and isomers, derivatives, salts thereof, wherein X4 is -COOH, -CH2COOH, substituted or unsubstituted alkyl-COOH, substituted or unsubstituted O-COOH, substituted or unsubstituted O-alkyl-COOH, substituted or unsubstituted alkyl-O-alkyl-COOH, etc. Specific implementation method:

[0041] Example

[0042] Synthesis part

[0043] Example 1: Synthesis of PACE-modified cap analogs using intermediates A and B as raw materials

[0044] Intermediate A (2.0 mol) was suspended in a DMF solution containing ZnCl2 (20.0 mol). Intermediate B (1.8 mol) was added to the reaction mixture under ice-cooling. After stirring at room temperature for 24 hours, the reaction was terminated with 10 L of 0.25 M EDTA-Na2 solution. The mixture was loaded onto a DEAE Sephadex column. The product was eluted using a linear gradient of 0-1.0 M sodium chloride aqueous solution, nanofiltered to remove salt, and concentrated to obtain the desired product. The reaction scheme is as follows:

[0045] Among them, intermediate A is obtained by the following steps:

[0046] (1) 50.0 g of guanosine was weighed and dissolved in 500.0 mL of trimethyl phosphate. The reaction solution was cooled to 0°C and phosphorus oxychloride (1.8 eq.) was slowly added dropwise under a nitrogen atmosphere. After stirring at 0°C for 4 hours, the reaction was quenched by adding water. The reaction mixture was washed twice with dichloromethane to remove most of the trimethyl phosphate. The aqueous phase was concentrated under reduced pressure to remove the residual organic solvent and then purified by reverse phase preparative liquid chromatography and concentrated to obtain intermediate A1.

[0047] (2) Intermediate A1, triphenylphosphine (2.0 eq.), 2,2'-disulfide dipyridine (2.0 eq.), imidazole (8.0 eq.), and triethylamine (1.0 eq.) were dissolved in DMF and stirred at room temperature under nitrogen for 15 hours. After the reaction, the reaction solution was slowly added to a 4 M sodium perchlorate acetone solution to precipitate a solid. The filter cake was then filtered and thoroughly washed with acetone to obtain Intermediate A2.

[0048] (3) Triethylamine phosphate (3.0 eq.) and zinc chloride (8.0 eq.) were suspended in anhydrous DMF and stirred at room temperature for 5 minutes. Intermediate A2 was added to the reaction mixture in batches and stirred at room temperature for 5 hours. After the reaction was completed, the reaction was terminated with 10 volumes of 0.25 M EDTA-Na2 solution. The reaction mixture was purified by ion chromatography to obtain intermediate A3.

[0049] (4) Intermediate A3 was dissolved in 20 volumes of purified water. The reaction solution was cooled to 4°C, and dimethyl sulfate (6.0 eq.) was slowly added dropwise. During the process, the pH was adjusted to no more than 5 with 2 M sodium hydroxide. The reaction was monitored by HPLC. After the reaction was completed, the solution was washed with dichloromethane, and the aqueous phase was purified by ion chromatography to obtain intermediate A4.

[0050] (5) Intermediate A4, triphenylphosphine (2.0 eq.), 2,2'-disulfide dipyridine (2.0 eq.), imidazole (8.0 eq.), and triethylamine (1.0 eq.) were dissolved in DMF and stirred at room temperature under nitrogen for 10 hours. After the reaction, the reaction solution was slowly added to a 4 M sodium perchlorate acetone solution to precipitate a solid, which was then filtered and the filter cake was thoroughly washed with acetone to obtain Intermediate A. The reaction scheme is shown in the following equation.

[0051] Wherein, compound B is obtained by the following steps:

[0052] (1) Weigh 200.0 g of 2'OMe-rA phosphoramidite monomer containing PACE structure and N 2 -Isobutyryl-2',3'-acetylguanosine (1.0 eq.) was dissolved in 2.0 L of dichloromethane in a single-necked flask. Tetrazole (2.1 eq.) was added under nitrogen purge and allowed to react at 25°C for 3 hours. After the reaction was complete, a 70% aqueous solution of tert-butyl hydroperoxide was added dropwise to the reaction solution and allowed to react at 25°C for 1 hour. After the reaction was complete, a dichloromethane solution of trichloroacetic acid (4.0 eq.) was added dropwise to the reaction solution and allowed to react at room temperature for 1 hour. After the reaction was complete, the reaction solution was washed with 10% aqueous sodium sulfite solution, 10% aqueous sodium bicarbonate solution, and saturated brine, respectively. The organic phase was concentrated and purified by column chromatography to obtain intermediate B1.

[0053] (2) Dissolve the intermediate B1 in acetonitrile (10V), add 1.8eq. of bis(2-cyanoethyl)-N,N-diisopropylphosphoramidite and 1.8eq. of tetrazole, and stir at room temperature for 2 hours under nitrogen atmosphere. After the reaction is completed, add 70% tert-butyl hydroperoxide aqueous solution (1.2eq.) dropwise to the reaction solution and react at room temperature for 1 hour. After the reaction is completed, spin dry, add methanol (5V) and DBU (2.5eq.) to the spin flask and react at room temperature for 4 hours, then add concentrated ammonia (5V), react at room temperature for 14 hours, detect the reaction, and spin dry after the reaction is completed. The crude product is purified by ion chromatography and concentrated to obtain intermediate B. The reaction route flow is as follows:

[0054] Example 2: Synthesis of PACE-modified cap analogs using intermediates C and D as raw materials

[0055] Intermediates C and D were used as raw materials and the cap analogue of Example 2 was obtained by referring to the synthesis method of the target product in Example 1. The reaction scheme is as follows:

[0056] Wherein, compound C is obtained by the following steps:

[0057] (1) 50g N 2 -isobutyryl-2',3'-acetylguanosine was dissolved in dichloromethane (10V), 1.8eq. of intermediate C1 and 1.8eq. of tetrazole were added, and the mixture was stirred at room temperature under nitrogen atmosphere for 2 hours. 2 After the disappearance of the 2',3'-isobutyryl-2',3'-acetylguanosine, 70% aqueous tert-butyl hydroperoxide solution (1.2 eq.) was added dropwise to the reaction mixture and allowed to react at room temperature for 1 hour. After the reaction was complete, the reaction mixture was washed with 10% aqueous sodium sulfite solution and saturated brine, respectively. The organic phase was concentrated to obtain intermediate C2.

[0058] (2) Intermediate C2 was dissolved in methanol (5V), and DBU (2.5eq.) was added. The mixture was reacted at room temperature for 4 hours, and then concentrated aqueous ammonia (5V) was added. The mixture was reacted at room temperature for 14 hours. After the reaction was completed, the mixture was spin-dried. The crude product was purified by ion chromatography and concentrated to obtain intermediate C3.

[0059] (3) Intermediate C3 was dissolved in 20 volumes of purified water. The reaction solution was cooled to 4°C, and dimethyl sulfate (6.0 eq.) was slowly added dropwise. During the process, the pH was adjusted to no more than 5 with 2 M sodium hydroxide. The reaction was monitored by HPLC. After the reaction was completed, the solution was washed with dichloromethane, and the aqueous phase was purified by ion chromatography to obtain intermediate C.

[0060] Wherein, compound D is obtained by the following steps:

[0061] (1) Weigh 200.0 g of 2'OMe-rA phosphoramidite monomer and N 2 -Isobutyryl-2',3'-acetylguanosine (1.0 eq.) was dissolved in 2.0 L of dichloromethane in a single-necked flask. Tetrazole (2.1 eq.) was added under nitrogen purge and reacted at 25°C for 3 hours. After the detection reaction was completed, 70% tert-butyl hydroperoxide aqueous solution was added dropwise to the reaction solution and reacted at 25°C for 1 hour. After the detection reaction was completed, trichloroacetic acid (4.0 eq.) in dichloromethane was added dropwise to the reaction solution and reacted at room temperature for 1 hour. After the detection reaction was completed, the reaction solution was washed with 10% sodium sulfite aqueous solution, 10% sodium bicarbonate aqueous solution, and saturated brine, respectively. The organic phase was concentrated and purified by column chromatography to obtain intermediate D1.

[0062] (2) Intermediate D1 was dissolved in acetonitrile (10V), and 1.8eq. of bis(2-cyanoethyl)-N,N-diisopropylphosphoramidite and 1.8eq. of tetrazole were added, followed by stirring at room temperature for 2 hours under a nitrogen atmosphere. After the reaction, 70% aqueous tert-butyl hydroperoxide solution (1.2eq.) was added dropwise to the reaction solution, and the reaction was allowed to proceed at room temperature for 1 hour. After the reaction was completed, methanol and concentrated aqueous ammonia (10V, 1:1) were added to the flask, and the reaction was allowed to proceed at room temperature for 14 hours. The reaction was then monitored and the reaction was completed, followed by drying by spin-drying. The crude product was purified by ion chromatography and concentrated to obtain intermediate D2.

[0063] (3) Intermediate D2, triphenylphosphine (2.0 eq.), 2,2'-disulfide dipyridine (2.0 eq.), imidazole (8.0 eq.), and triethylamine (1.0 eq.) were dissolved in DMF and stirred at room temperature under nitrogen atmosphere for 15 hours. After the reaction, the reaction solution was slowly added to a 4 M sodium perchlorate acetone solution to precipitate a solid. The filter cake was then filtered and thoroughly washed with acetone to obtain Intermediate D3.

[0064] (4) Triethylamine phosphate (3.0 eq.) and zinc chloride (8.0 eq.) were suspended in anhydrous DMF and stirred at room temperature for 5 minutes. Intermediate A3 was added to the reaction solution in batches and stirred at room temperature for 5 hours. After the reaction was completed, the reaction was terminated with 10 volumes of 0.25 M EDTA-Na2 solution. The reaction solution was purified by ion chromatography to obtain intermediate D4.

[0065] (5) Intermediate D4, triphenylphosphine (2.0 eq.), 2,2'-disulfide dipyridine (2.0 eq.), imidazole (8.0 eq.) and triethylamine (1.0 eq.) were dissolved in DMF and stirred at room temperature under nitrogen atmosphere for 10 hours. After the reaction, the reaction solution was slowly added to a 4 M sodium perchlorate acetone solution to precipitate a solid, which was then filtered and the filter cake was thoroughly washed with acetone to obtain intermediate D. The reaction route is as follows:

[0066] Example 3: Synthesis of PACE-modified cap analogs using intermediates E and F as raw materials

[0067] Intermediates E and F were used as starting materials and the cap analogue of Example 3 was obtained by referring to the synthesis method of the target product in Example 1. The reaction scheme is as follows:

[0068] Wherein, compound E is obtained by the following steps:

[0069] (1) Intermediate A1 was dissolved in 20 volumes of purified water. The reaction solution was cooled to 4°C and dimethyl sulfate (6.0 eq.) was slowly added dropwise. During the process, the pH was adjusted to no more than 5 with 2 M sodium hydroxide. The reaction was monitored by HPLC. After the reaction was completed, the solution was washed with dichloromethane and the aqueous phase was purified by ion chromatography to obtain intermediate E1.

[0070] (2) Intermediate E1, triphenylphosphine (2.0 eq.), 2,2'-disulfide dipyridine (2.0 eq.), imidazole (8.0 eq.) and triethylamine (1.0 eq.) were dissolved in DMF and stirred at room temperature under nitrogen atmosphere for 10 hours. After the reaction, the reaction solution was slowly added to a 4 M sodium perchlorate acetone solution to precipitate a solid, which was then filtered and the filter cake was thoroughly washed with acetone to obtain intermediate E. The reaction route is as follows:

[0071] Compound F was obtained by suspending phosphoacetic acid (3.0 eq.) and zinc chloride (8.0 eq.) in anhydrous DMF and stirring at room temperature for 5 minutes. Intermediate D3 was added to the reaction mixture in portions and stirred at room temperature for 5 hours. After completion, the reaction was terminated with 10 volumes of 0.25 M EDTA-Na2 solution. The reaction mixture was purified by ion chromatography to obtain Intermediate F.

[0072] Example 4: Synthesis of PACE-modified cap analogs using intermediates A and H as raw materials

[0073] Using intermediates A and H as raw materials, the cap analog of Example 4 was obtained by referring to the synthesis method of the target product in Example 1. The reaction scheme is as follows:

[0074] Wherein, compound H is obtained by the following steps:

[0075] (1) 50 g of intermediate D1 was dissolved in dichloromethane (10 V), 1.8 eq. of intermediate C1 and 1.8 eq. of tetrazole were added, and the mixture was stirred at room temperature under nitrogen for 2 hours. After the complete consumption of intermediate D1 was detected by spot plate detection, 70% aqueous tert-butyl hydroperoxide solution (1.2 eq.) was added dropwise to the reaction solution and reacted at room temperature for 1 hour. After the reaction was completed, the reaction solution was washed with 10% aqueous sodium sulfite solution and saturated brine, respectively, and the organic phase was concentrated to obtain intermediate H1.

[0076] (2) Intermediate H1 was dissolved in methanol (5V), DBU (2.5eq.) was added, and the mixture was reacted at room temperature for 4 hours. Concentrated ammonia (5V) was added and the mixture was reacted at room temperature for 14 hours. After the reaction was complete, the mixture was spin-dried. The crude product was purified by ion chromatography and concentrated to obtain intermediate H.

[0077] Example 5: Synthesis of PACE-modified cap analogs using intermediates A and I as raw materials

[0078] Using intermediates A and I as raw materials, the cap analog of Example 5 was obtained by referring to the synthesis method of the target product in Example 1. The reaction scheme is as follows:

[0079] Wherein, compound I is obtained by the following steps:

[0080] (1) 30 g of intermediate B1 was dissolved in dichloromethane (10 V), 1.8 eq. of intermediate C1 and 1.8 eq. of tetrazole were added, and the mixture was stirred at room temperature under nitrogen for 2 hours. After the complete consumption of intermediate B1 was detected by spot plate detection, 70% aqueous tert-butyl hydroperoxide solution (1.2 eq.) was added dropwise to the reaction solution and reacted at room temperature for 1 hour. After the reaction was completed, the reaction solution was washed with 10% aqueous sodium sulfite solution and saturated brine, respectively, and the organic phase was concentrated to obtain intermediate I1.

[0081] (2) Intermediate I1 was dissolved in methanol (5V), and DBU (2.5eq.) was added. The mixture was reacted at room temperature for 4 hours, and then concentrated aqueous ammonia (5V) was added. The mixture was reacted at room temperature for 14 hours. After the reaction was completed, the mixture was spin-dried. The crude product was purified by ion chromatography and concentrated to obtain intermediate I.

[0082] Example 6: Synthesis of PACE-modified cap analogs using intermediates A and J as raw materials

[0083] Intermediates A and J were used as starting materials and the cap analogue of Example 6 was obtained by referring to the synthesis method of the target product in Example 1. The reaction scheme is as follows:

[0084] Wherein, compound J is obtained by the following steps:

[0085] (3) Weigh 150.0 g of 2'OMe-rA phosphoramidite monomer containing PACE derivative structure and N 2 -Isobutyryl-2',3'-acetylguanosine (1.0 eq.) was dissolved in 2.0 L of dichloromethane in a single-necked bottle. Tetrazole (2.1 eq.) was added under nitrogen purge and reacted at 25°C for 3 hours. After the detection reaction was completed, 70% tert-butyl hydroperoxide aqueous solution was added dropwise to the reaction solution and reacted at 25°C for 1 hour. After the detection reaction was completed, trichloroacetic acid (4.0 eq.) in dichloromethane was added dropwise to the reaction solution and reacted at room temperature for 1 hour. After the detection reaction was completed, the reaction solution was washed with 10% sodium sulfite aqueous solution, 10% sodium bicarbonate aqueous solution, and saturated brine, respectively. The organic phase was concentrated and purified by column chromatography to obtain intermediate J1.

[0086] (4) Dissolve the intermediate J1 in acetonitrile (10V), add 1.8eq. of bis(2-cyanoethyl)-N,N-diisopropylphosphoramidite and 1.8eq. of tetrazole, and stir at room temperature for 2 hours under nitrogen atmosphere. After the reaction is completed, add 70% tert-butyl hydrogen peroxide aqueous solution (1.2eq.) dropwise to the reaction solution and react at room temperature for 1 hour. After the reaction is completed, spin dry, add methanol (5V) and DBU (2.5eq.) to the spin flask and react at room temperature for 4 hours, then add concentrated ammonia (5V), react at room temperature for 14 hours, detect the reaction, and spin dry after the reaction is completed. The crude product is purified by ion chromatography and concentrated to obtain intermediate J. The reaction route flow is as follows:

[0087] Comparative Example 1 Synthesis of Cap Analogs Using Intermediates A and D2 as Raw Materials

[0088] Using intermediates A and D2 as raw materials, the cap analog of Comparative Example 1 was obtained by referring to the synthesis method of the target product in Example 1. The reaction route is as follows:

[0089] Biological activity detection

[0090] 1. Determination of mRNA in vitro transcription yield and capping efficiency

[0091] In vitro synthesis of mRNA using cap analogs modified with PACE structure: linear endonuclease digestion of plasmid; extraction of linearized DNA template; in vitro transcription synthesis of mRNA. The cap analogs of Examples 1-6 and Comparative Example 1 were used as cap structures.

[0092] The reaction system is shown in Table 1:

[0093] Table 1 In vitro transcription reaction system

[0094] Note: During the experiment, first calculate the required volume of the system and then add the sample. First, add sterile, enzyme-free water to the system, followed by 10X buffer, NTPs, and cap analogs. Mix thoroughly and centrifuge gently. Then, add nuclease inhibitors, inorganic pyrophosphatase, T7 RNA polymerase, and linearized DNA template. Mix thoroughly and centrifuge gently. After incubation at 37°C for 2 hours, add 1U of DNase I and continue incubation at 37°C for 30 minutes to remove the DNA template. Purify the mRNA using magnetic beads. Dissolve the purified mRNA in sterile, enzyme-free water and measure the mRNA yield using a Nanodrop One instrument.

[0095] Liquid chromatography-mass spectrometry (LC-MS) is used to measure the IVT capping rate of mRNA with different initiation cap analogs. First, a labeled DNA probe is designed that matches the start base of the transcript mRNA, typically with a biotin tag. After washing, the streptavidin-labeled magnetic beads are incubated with the synthesized DNA probe, mRNA, and 10× RNase H reaction buffer at room temperature for 30 minutes, gently mixing. Subsequently, 20 μl of RNase H (5 U / μl) is added and incubated at 37°C for 3 hours, mixing every half hour. After incubation, the beads are washed and 100 μl of 75% methanol heated to 80°C is added. The mixture is heated to 80°C on a hot plate for 3 minutes, then placed on a magnetic rack, the supernatant is aspirated, and dried in an evaporative centrifuge at room temperature for 45 minutes to a volume of 10 μl. The sample is then resuspended in 50 μl of 100 μM EDTA / 1% MeOH for LC-MS analysis to determine the capping status of the transcription reaction. Since there is a significant difference in molecular weight between capped and non-capped bases, the difference in molecular mass can be used to determine the capping rate of mRNA transcription initiated by different cap analogs.

[0096] As shown in Table 2, the PACE-structured cap analogs of Examples 1-6 can all be transcribed into the corresponding target mRNA, and the yields and capping rates of the PACE-structured cap analogs of Examples 1-6 are significantly better than those of Comparative Example 1.

[0097] Table 2 mRNA in vitro transcription yield and capping rate

[0098] 2. Detection of mRNA translation efficiency

[0099] Using the eGFP coding sequence as a DNA template and the cap analogs of Examples 1-6 and Comparative Example 1 as an initiator, in vitro transcription was performed, and the mRNA synthesized by in vitro transcription was transfected into 293T cells.

[0100] 293T cells were expressed at (0.5-1)×10 5 Cells were plated (24-well plates). It is recommended to use cells within 50 generations for transfection experiments. The cells were required to be passaged again 24 hours before transfection. Adding antibiotics to the culture medium has no effect on the transfection effect. During transfection, the cell density is generally 60-80% for best results. 2 μg of mRNA was transfected per well. The transfection reagent used was Lipofectamine MessengerMAX Transfection Reagent (Invitrogen) and the operation was performed according to its instructions. The transfected cells were placed in a 37°C, CO2 incubator. After 4-6 hours of transfection, the culture medium was replaced with fresh complete medium. After incubation in a 37°C CO2 incubator for 24 hours, the fluorescence intensity of GFP was observed under a fluorescence microscope.

[0101] The results are shown in Table 3. The efficiency of in vitro transcribed mRNAs synthesized in Examples 1-6 in cellular protein translation was significantly higher than that in Comparative Example 1, and none of them caused significant cell death. These experimental data demonstrate that the PACE-modified cap analogs described herein can be efficiently applied for in vitro mRNA transcription and intracellular protein expression.

[0102] Table 3 Translation and expression efficiency of intracellular mRNA

Claims

1. A PACE structure-modified cap analog, wherein the structure of the cap analog has nucleoside bases or modified nucleoside bases at both ends, three ribose structures in the middle and a triphosphonate segment or a phosphonate segment connecting the ribose structures, characterized in that: The triphosphonate segment or phosphonate segment has one or more PACE structures or PACE-derived structures, and the PACE structure or PACE-derived structure conforms to the following general structural formula: X of the PACE structure is -CH2COOH or a salt thereof; X of the PACE-derived structure is -COOH, substituted or unsubstituted alkyl-COOH or a salt thereof, substituted or unsubstituted O-alkyl-COOH or a salt thereof, substituted or unsubstituted alkyl-O-COOH or a salt thereof, substituted or unsubstituted alkyl-O-alkyl-COOH or a salt thereof; the carbon number of the alkyl group mentioned above is not more than 7; the substituent mentioned above refers to an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl group having a carbon number not more than 7.

2. The PACE structure-modified cap analog according to claim 1, characterized in that The salt refers to a sodium salt, an ammonium salt or a salt formed with tris(hydroxymethyl)aminomethane.

3. The PACE structure-modified cap analogue according to claim 1 or 2, characterized in that: The X is an alkyl-COOH or a salt thereof, and the number of carbon atoms in the alkyl group is 1, 2, 3 or 4.

4. The PACE structure-modified cap analog according to claim 1 or 2, characterized in that: The X is O-alkyl-COOH, and the number of carbon atoms in the alkyl group is 1, 2, 3 or 4.

5. The PACE structure-modified cap analogue according to any one of claims 1 to 4, characterized in that: It conforms to the following structural formula: wherein R1, R2 and R3 are independently H, OH, F, alkyl, substituted or unsubstituted O-alkyl; R4 is selected from OH or O-alkyl; Any one, two or more of X1, X2, X3 and X4 are X as described in claim 1, and the rest are independently H, OH, NH2, alkyl, O-alkyl, N-alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or halogen; B1 and B2 are each independently a natural, modified or non-natural nucleobase.

6. The PACE structure-modified cap analogue according to any one of claims 1 to 4, characterized in that: It conforms to the following structural formula: wherein R1, R2 and R3 are independently H, OH, F, alkyl or O-alkyl; Any one, two or more of X1, X2, X3 and X4 are X as described in claim 1, and the rest are independently H, OH, NH2, alkyl, O-alkyl, N-alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or halogen; B1 and B2 are each independently a natural, modified or non-natural nucleobase.

7. The PACE structure-modified cap analogue according to any one of claims 5 to 6, characterized in that: B1 and B2 are independently adenine (A), guanine (G), cytosine (C), uracil (U), thymine (T) or adenine substituted with a methyl group.

8. The PACE structure-modified cap analogue according to claim 7, characterized in that B1 and B2 are each independently adenine (A), guanine (G), or adenine substituted with a methyl group.

9. The PACE structure-modified cap analogue according to any one of claims 1 to 8, characterized in that: It can be any of the following structures:

10. The PACE structure-modified cap analogue according to any one of claims 1 to 8, characterized in that: It is a salt form of any one of the following structures, wherein the salt form is a sodium salt, an ammonium salt or a salt formed by tris(hydroxymethyl)aminomethane of the following structure:

11. Use of a PACE structure-modified cap analogue according to any one of claims 1 to 10, characterized in that: RNA is capped during in vitro transcription reactions and used for in vitro transcription preparation of linear mRNA.

12. The use according to claim 11, characterized in that: The application steps are as follows: Step (1): preparing a DNA template; Step (2): performing an in vitro transcription reaction, wherein the reaction system contains RNA polymerase, nucleoside triphosphonate and the PACE structure-modified cap analog.

Citation Information

Patent Citations

  • Cap analogue modified by PACE structure and application thereof

    CN116554250A

  • mRNA cap analogue and use thereof

    WO2023033551A1